This database contains 750 studies, archived under the term: "aged, 80 and over"
Click here to filter this large number of results.
The social treatment: the benefits of group interventions in residential care settings
Haslam, Catherine,
Haslam, S. Alexander,
Jetten, Jolanda,
Bevins, Adam,
Ravenscroft, Sophie,
Tonks, James
We report findings from an intervention study that investigates the impact of group reminiscence (GR) and individual reminiscence (IR) activities on older adults living in care settings. This research aimed to provide a theory-driven evaluation of reminiscence based on a social identity framework. This framework predicts better health outcomes for group-based interventions as a result […]
Counsellors contact dementia caregivers–predictors of utilisation in a longitudinal study
Grossfeld-Schmitz, Maria,
Donath, Carolin,
Holle, Rolf,
Lauterberg, Joerg,
Ruckdaeschel, Stephan,
Mehlig, Hilmar,
Marx, Peter,
Wunder, Sonja,
Grässel, Elmar
Background: Counselling of family members is an established procedure in the support of dementia patients’ relatives. In absence of widespread specialised dementia care services in most countries, however, counselling services are often not taken up or only very late in the course of the disease.; Object: In order to promote acceptance of this service, a […]
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
Feldman, H. H.,
Doody, R. S.,
Kivipelto, M.,
Sparks, D. L.,
Waters, D. D.,
Jones, R. W.,
Schwam, E.,
Schindler, R.,
Hey-Hadavi, J.,
DeMicco, D. A.,
Breazna, A.
Background: There is some evidence that statins may have a protective and symptomatic benefit in Alzheimer disease (AD). The LEADe study is a randomized controlled trial (RCT) evaluating the efficacy and safety of atorvastatin in patients with mild to moderate AD.; Methods: This was an international, multicenter, double-blind, randomized, parallel-group study. Subjects had mild to […]
Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer’s disease: A 24-week, randomized, double-blind study
Farlow, Martin R.,
Salloway, Stephen,
Tariot, Pierre N.,
Yardley, Jane,
Moline, Margaret L.,
Wang, Qin,
Brand-Schieber, Elimor,
Zou, Heng,
Hsu, Timothy,
Satlin, Andrew
Background: Currently approved Alzheimer’s disease (AD) treatments have been reported to provide symptomatic benefit, without proven impact on clinical progression. We hypothesized that the loss of initial therapeutic benefit over time may be mitigated by higher doses of a cholinesterase inhibitor.; Objective: The aim of this study was to determine the effectiveness and tolerability of […]
Effects of general practitioner training and family support services on the care of home-dwelling dementia patients–results of a controlled cluster-randomized study
Donath, Carolin,
Grässel, Elmar,
Grossfeld-Schmitz, Maria,
Menn, Petra,
Lauterberg, Jörg,
Wunder, Sonja,
Marx, Peter,
Ruckdäschel, Stephan,
Mehlig, Hilmar,
Holle, Rolf
Background: More than 90% of dementia patients are cared for by their general practitioners, who are decisively involved in the diagnosis, therapy and recommendation of support services.; Objective: To test whether special training of general practitioners alters the care of dementia patients through their systematic recommendation of caregiver counseling and support groups.; Method: 129 general […]
Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms
Dombrovski, Alexandre Y.,
Mulsant, Benoit H.,
Ferrell, Robert E.,
Lotrich, Francis E.,
Rosen, Jules I.,
Wallace, Meredith,
Houck, Patricia R.,
Mazumdar, Sati,
Pollock, Bruce G.
The risk/benefit ratio of pharmacotherapy for behavioral symptoms of dementia is questionable: second-generation antipsychotics are poorly tolerated, and the efficacy of alternative treatments, for example, selective serotonin-reuptake inhibitors (SSRIs), is uncertain. Biomarkers of treatment response may improve this risk/benefit ratio. The length polymorphism of the serotonin transporter promoter gene (5-HTTLPR/SLC6A4) may moderate tolerability of SSRIs […]
Low-dose divalproex in agitated patients with Alzheimer’s disease
Adequate treatment of behavioral disturbances in Alzheimer’s disease is both important and difficult. This report describes a case series that examined the effectiveness and safety of low-dose divalproex in the treatment of agitated patients with Alzheimer’s disease who were admitted to an inpatient geriatric psychiatry unit over a 1-year period. All patients had agitation due […]